Salvage chemotherapy followed by autologous stem cell transplant (ASCT) remains the
current standard of care for patients with relapsed or refractory diffuse large B‐cell lymphoma (…

Objective. A prospective observational study of mycophenolate mofetil (MMF) treatment in
patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset. Methods. …

We conducted a phase I/II multicenter trial using six cycles of brentuximab vedotin (BV) in
combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for …

Chimeric antigen receptor T‐cell therapy (CAR T) is a novel intervention for relapsed/refractory
diffuse large B‐cell lymphoma (R/R DLBCL) and other hematologic malignancies. …

Molecular imaging with 18 F-Fluorodeoxyglucose positron emission tomography/computed
tomography (FDG-PET/CT) is an established modality for response assessment in patients …

Background: Follicular lymphoma (FL) remains an incurable disease for most patients (pts),
characterized by a relapsing and remitting pattern. For pts with relapsed/refractory (r/r) FL, …

Background Falls are a major public health concern in older adults, and the proportion of
older adults that has been diagnosed with cancer is growing. Yet, while falls, peripheral …

Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse
following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. …

Aim: To describe the long-term outcomes of patients with lymphoma in the CNS treated with
rituximab, temozolomide and high-dose methotrexate without consolidation therapy. …

Posttransplant lymphoproliferative disorders (PTLD) represent immunosuppression-related
lymphoid or plasmacytic proliferation that occur in the setting of solid organ or allogeneic …